Inhibition of phosphoinositide 3-kinase is associated with reduced angiogenesis and an altered expression of angiogenic markers in endothelioma cells.

The phosphoinositide 3-kinase (PI3k) signaling pathway is involved in the regulation of numerous cellular activities. The pathway has also been implicated in the development of various tumors. In the context of vascular tumors, the role of the PI3k signaling still needs to be established. In the present study, the effects of blocking PI3k activation on endothelioma cells derived from mice with vascular tumors were investigated using the crystal violet assay, real-time cell analysis, light microscopy, the aorta ring assay and antibody arrays. The suppression of PI3k led to the inhibition of cell growth, cell migration, as well as angiogenesis. The inhibition of these processes correlated with low Akt activity. Antibody array analysis revealed that there was a suppression of several proangiogenic molecules, including Eotaxin-1 and basic fibroblast growth factor (bFGF) in cultures treated with LY294,002, an inhibitor of PI3k. At the same time, LY294,002 increased the expression of platelet factor 4 (PF4) and the Fas ligand (FasL), molecules which have antiangiogenic properties. The results suggest that PI3k may play a role in the expression of some of the key regulatory molecules involved in angiogenesis, and perhaps in the growth of endotheliomas. As such, it is plausible that the PI3k/Akt pathway may be a target for therapeutic molecules designed for the treatment of endothelial tumors.

Decreased secretion of vascular endothelial growth factor is associated with increased apoptosis in vascular tumor derived endothelial cells.

Bleomycin is an antineoplastic drug that has recently been employed to treat haemangiomas, the most common vascular tumors of infancy, with very good results. To better understand the mechanism of bleomycin in accelerating haemangioma regression, we have investigated the effects of the drug on vascular tumor inducing endothelial cells (sEnd.2 cells). Cell growth studies were undertaken using crystal violet staining, while morphological studies were undertaken employing transmission electron microscopy. The cells were analyzed for possible apoptosis employing flow cytometry. The expression of Bcl-2 and p53 were investigated using Western blot analysis. In addition, the production of vascular endothelial growth factor was measured using ELISA. Results showed that bleomycin inhibited the growth of these endothelial cells, even in the presence of vascular endothelial growth factor, a proangiogenic growth factor. Further, there was increased endothelial cell apoptosis, as evidenced by morphological analysis, increased acridine orange staining of cell nuclei and annexin V staining. Apoptosis was associated with an increase in the expression of p53 and a decrease in the expression of the antiapoptotic protein Bcl-2.

Vascular endothelial growth factor concentrations in dogs with spirocercosis.

BACKGROUND: Vascular endothelial growth factor (VEGF) is a potent proangiogenic factor associated with tumor development. Spirocerca lupi is a nematode of canids that induces an esophageal nodule that progresses to a sarcoma in 25% of cases. Determination of neoplastic transformation is challenging and usually based on endoscopy-guided biopsies under general anesthesia, an expensive procedure that often yields nondiagnostic, necrotic samples. HYPOTHESIS: Circulatory VEGF concentrations are increased in dogs with neoplastic spirocercosis and can distinguish between dogs with neoplastic and nonneoplastic disease. ANIMALS: A total of 24 client-owned dogs, 9 nonneoplastic, 9 neoplastic, and 6 controls. METHODS: Case-control study. Plasma and serum VEGF concentrations at the time of diagnosis were compared with those of healthy controls. Measurement of VEGF was performed using a canine-specific ELISA. Kruskal-Wallis and Dunn's tests were used for statistical analysis with significance set at P < .05. RESULTS: The median plasma VEGF concentrations of dogs with neoplastic spirocercosis were 629 pg/mL (range, 282-2,366) higher than both the nonneoplastic (<39.5 pg/mL; range, <39.5-716) and control dogs (<39.5 pg/mL; all values, <39.5; P = .0003). The median serum VEGF concentration of the neoplastic dogs was 69 pg/mL (range, <39.5-212) higher than the nonneoplastic (<39.5 pg/mL; range, <39.5-44.13) and control dogs (<39.5 pg/mL; all values, <39.5; P = .001). CONCLUSIONS AND CLINICAL IMPORTANCE: Both plasma and serum VEGF concentrations can be used to differentiate nonneoplastic and neoplastic spirocercosis. The role of VEGF in neoplastic transformation of S. lupi-induced nodules and the potential utility of anti-VEGF drugs in spirocercosis-induced sarcoma warrant further investigation.